Tschop recounted his research with DiMarchi and that of others while he accepted the 2023 Banting Medal for Scientific Achievement at the 2023 American Diabetes Association Scientific Sessions.5 The FDA approved the first GLP-1 agonist, twice-a-day Byetta (exenatide), in 2005.1 Since then, several newer and more powerful medications in the GLP-1 agonist class, such as liraglutide and semaglutide, have received FDA approval for type 2 diabetes, with a higher dose of semaglutide FDA approved for weight loss.2 In mid-2022, the first dual agonist, tirzepetide (a combination of a GLP-1 agonist and a GIP), was FDA approved for type 2 diabetes
Efficacy comparison by clinical trial data The most relevant head-to-head data comes from the SURPASS-2 trial (tirzepatide vs semaglutide 1 mg for type 2 diabetes) and the SURMOUNT-5 trial (tirzepatide vs semaglutide 2.4 mg for obesity)
These are hard risk factors for heart disease
Among 331,863 matched GLP-1RAs users, the hazard ratios for pneumonia and severe sepsis were 0.60 (95% CI, 0.580.62) and 0.61 (95% CI, 0.590.63), respectively, indicating a substantial risk reduction relative to the DPP-1 is cohort ( , IL-1, IL-6, CXCL1), suppression of neutrophil infiltration, and decreased expression of genes associated with tissue remodeling and inflammation (Mmp9, Timp1, Ly6g)
